Tessera Therapeutics

About

Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.

Cambridge,Massachusetts,United States
101 - 250
https://www.tesseratherapeutics.com

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $300M
Industries: Biopharma,Biotechnology,Genetics,Life Science,Therapeutics
Founded date: Jan 1, 2018
Number Of Employee: 101 - 250
Operating Status: Active
Legal Name: Tessera Therapeutics, Inc.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$530M $2.70M

Tessera Therapeutics has raised a total of $530M $2.70M in funding over 2 rounds. Their latest funding was raised on Apr 19, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 19, 2022	Series C	$300M	12	—	—	Detail
Jan 12, 2021	Series B	$230M	6	Alaska Permanent Fund SoftBank Vision Fund	—	Detail
May 7, 2020	Seed	$2.70M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

13

Tessera Therapeutics is funded by 13 investors. Abu Dhabi Investment Authority and Alaska Permanent Fund are the most recent investors.

Investor Name	Lead Investor	Funding Round
Abu Dhabi Investment Authority	—	Series C
Alaska Permanent Fund	—	Series C
Altitude Life Science Ventures	—	Series C
Artis Ventures (AV)	—	Series C
Cormorant Asset Management	—	Series C
Flagship Pioneering	—	Series C
Hanwha Impact Partners	—	Series C
Longevity Vision Fund	—	Series C
March Capital	—	Series C
SALT Fund	—	Series C